Inflammatory Mediators in Erythema Migrans

University Medical Centre Ljubljana

Status: Completed

Conditions: Erythema Migrans

Treatments: Drug: Doxycycline 7 days; Drug: Doxycycline 14 days

Study type: Interventional

Funder types: Other

Identifiers

NCT03956212

EM Doxy-2017

Details and patient eligibility

About

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• erythema migrans in patients > 18 years

Exclusion criteria

• pregnancy or immunocompromising conditions
• taking antibiotic with antiborrelial activity within 10 days

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

erythema migrans patients treated with doxycycline

Experimental group

Description:

adult patients with erythema migrans will be treated with oral doxycycline

Treatment:

Drug: Doxycycline 7 days

Drug: Doxycycline 14 days